For increasing numbers of companies that have been launched on a discovery platform technology, the focus has turned to efforts to broaden their core competencies in order to capture the complete technology base that - it is increasingly clear - will be necessary to become a sustainable business (see Who Survives, BioCentury Feb. 10).

In the latest permutation of this approach, Bristol-Myers Squibb, The Whitehead Institute/MIT Center for Genome Research, Affymetrix Inc. (AFFX) and Millennium Pharmaceuticals Inc. (MLNM) last week announced the formation of a consortium that will integrate the technologies of AFFX and MLNM with Bristol-Myers's pharmaceutical know-how in drug discovery to develop new technologies.